The results revealed that GBMLGG, LUAD, and PAAD patients with high expression of PLPP4 exhibited shorter overall survival rates compared with the corresponding patients with “low” or “none” expression of PLPP4 (Figures 4C, , G, J). Here, PLPP4 is linked to pancreatic adenocarcinoma.